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Background: Next-generation sequencing (NGS) studies have shown that mul-
tiple myeloma is a heterogeneous disease with a complex subclonal architecture
and few recurrently mutated genes. The analysis of smaller regions of interest
in the genome (“targeted studies”) allows interrogation of recurrent genomic
events with reduces complexity of downstream analysis at a lower price. 
Aims: Here, we performed the largest targeted study to date in multiple myelo-
ma to analyze gene mutations, deletions and amplifications, chromosomal
copy number changes and immunoglobulin heavy chain locus (IGH) translo-
cations and correlate results with biological and clinical features. 
Methods: We used Agilent SureSelect cRNA pull down baits to target: 246
genes implicated in myeloma or cancer in general in a mixed gene
discovery/confirmation effort; 2538 single nucleotide polymorphisms to detect
amplifications and deletions at the single-gene and chromosome level; the IGH
locus to detect translocations. We sequenced unmatched DNA from CD138-
purified plasma cells from 418 patients with multiple myeloma at diagnosis, with
a median follow-up of 5.3 years. We sequenced at an average depth of 337x
using Hiseq2000 machines (Illumina Inc.). We applied algorithms developed in-
house to call genomic events, filtering out potential artifacts and germline vari-
ants. We then ranker each event on its likelihood of being “oncogenic” based
on clustering, recurrence and cross-reference with the COSMIC database. 
Results: We identified 2270 gene mutations in 412/418 patients, and of those
688 were oncogenic. 342 patients harbored at least one oncogenic mutation.
215/246 genes showed at lease one likely somatic mutation, but only 106
showed at least one oncogenic mutation. 63% of oncogenic mutations were
accounted for by the top 9 driver genes previously identified (KRAS, NRAS,
TP53, FAM46C, BRAF, DIS3, TRAF3, SP140, IRF4), implying our gene discov-
ery effort did not identify novel mutated genes. We included deletion of tumor
suppressors, amplification of oncogenes, chromosomal copy number changes
and IGH translocations for a total of 76 variables, so that 413/418 patients
showed at least one informative driver genomic event, (median 4/patient). We
investigated pairwise associations between events and found significant corre-
lations, such as TP53 mutations and del(17p), CYLD mutations and del(16),
FAM46C mutations and del(1p), SF3B1 mutations and t(11;14). Hotspots muta-
tions of IRF4 lysine p.123 showed an inverse correlation with a hyperdiploid
karyotype and del(16) as opposed to other missense mutations scattered along
the gene, which has pathogenic implications. Survival was negatively affected
by the cumulative burden of lesions in an almost linear fashion, with median
survival of 10.97 and 4.07 years in patients with <=2 or >=7 lesions respectively,
and this was independent of the nature of the genomic events. Given the het-
erogeneity and complex interplay of the variables we fitted a cox-proportional
hazard model to predict survival. We found that mutations in TP53, amplifications
of MYC, deletions of CYLD, amp(1q), del12p13.31 and del17p13 where the
only significant events, all promoting shorter survival. In particular, TP53 muta-
tions and deletions, often co-occurring, had an additive effect so that carriers of
both showed a dismal survival of 17 months (Figure 1).
Figure 1.
Summary/Conclusions: Due to the complex genomic landscape in MM, a
discovery effort still requires large studies to derive significant associations.
We conclude that a targeted sequencing approach may provide prognostic
models and give insights into myeloma biology. 
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A NEW MULTIPLE MYELOMA CLASSIFICATION SYSTEM THAT
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Background: Today’s diagnostic tests for multiple myeloma (MM) reflect the
criteria of the updated WHO classification based on biomarkers and clinico-
pathologic heterogeneity.
Aims: To that end, we propose a new biological subtyping of myeloma plasma
cells (mPC) by B-cell subset associated gene signatures (BAGS), from the
normal B-cell hierarchy in the bone marrow (BM). Here we document the prog-
nostic and biological value of subtyping, as shown for DLBCL (JCO 2015 Apr
20; 33:1379).
Methods: We combined FACS and GEP to generate BAGS classifiers for
the normal BM subsets: PreB-I, PreB-II, immature (Im), naive (N), memory
(M) and PC. Construction was based on median-centred probe sets from
the BM data using regularized multinomial regression with six discrete out-
comes representing BAGS, by a total of 55 genes varying from 15-24 per
subtype. Each patient underwent BAGS assignment according to the high-
est predicted probability score above 0.45 or was otherwise unclassified.
The impact of BAGS was analyzed using six clinical cohorts, gathered
across geographical regions, time eras, and sampling methods. The analy-
sis estimated subtype frequencies and included a prognostic meta-analysis
of 926 patients treated with high dose melphalan as first line therapy in 3
prospective trials: UAMS, HOVON65/GMMG-HD4, MRC Myeloma IX data
with the Affymetrix U133 plus 2.0 microarray data available from myeloma
PC samples. To compensate for cohort-wise technical batch effects, each
cohort was median centred and adjusted probe set-wise to have same vari-
ance as the BM data.
Results: Validation of the normal B-cell subset phenotypes. Normalized his-
tograms of the fluorescence intensities (FI) of CD markers based on merged
multiparametric flow cytometry reanalysis of pure sorted populations resulting
from seven independent sorting procedures documented high purity. Principal
component analysis (PCA) of the FI for each sorted cell in all samples docu-
mented specificity. Surface markers, transcription factors, and B-cell differen-
tiation–specific genes were identified through a literature review, and their
expression across subsets was evaluated. The most varying probe sets were
included in an unsupervised hierarchical clustering analysis, supporting the
biological differences. Validation of MM patients subtyping by prognosis. The
resultant tumor assignments exhibited very similar BAGS subtype frequencies,
across 1302 individual MM cases from 4 different cohorts. The 5 BAGS sub-
types of 926 MM cases were significantly associated with overall (P=5.2x10-
8) and progression free (P=1.5x10-6) survival in a meta-analysis of patients in
the 3 clinical trials. The major impact was observed within the PreB-II and M
subtypes conferred with significant increased ISS stage III and inferior prog-
nosis compared to the Im, N and PC subtypes. Cox proportional hazard meta-
analysis showed that the five BAGS subtypes added significant and inde-
pendent prognostic information to the TC classification system and plasma
Beta-2 microglobulin level. In parallel we found significant correlation between
the PreBII subtypes and the proliferation index, risk profiling (P<0.0001) and
Beta-2 microglobulin (P<0.001).
Summary/Conclusions: We have documented patient specific mPC dif-
ferences with prognostic impact in support of reversible phenotypic plas-
ticity in MM. This observation provides a new model for generating insight
into the stages of clonal plasticity associated with oncogenesis and dedif-
ferentiation.
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